^
Association details:
Biomarker:ALK fusion
Cancer:Lung Adenocarcinoma
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report

Published date:
01/25/2023
Excerpt:
A 70-year-old woman complained of a cough with blood in her sputum...A stage IVa (cT4N1M1a) lung adenocarcinoma with ALK fusion was diagnosed….One year later, crizotinib was readministered at a half-dose because of disease progression, and the patient achieved stable disease without hepatotoxicity for 9 months.
DOI:
10.2147/OTT.S393165
Evidence Level:
Sensitive: C4 – Case Studies
Title:

68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report

Published date:
08/23/2020
Excerpt:
The patient with positive ALK fusion mutation started crizotinib treatment in July 2014. The patient's last response assessment was in March 2020, with 68-progression-free disease with crizotinib....crizotinib in a 68-months progression-free survival in a 62-years old non-smoking female patient with metastatic lung adenocarcinoma...
DOI:
10.1177/1078155220951242